RecruitingNCT06847542
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
PHASE3 · 250 planned enrolment
- Countries listed
- 13
- Registry update
- September 21, 2026
immortal.lifeTrial registrations containing the exact intervention label Susvimo PDS Implant.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE3 · 250 planned enrolment